Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024 Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the Company or Spyre ), a clinical-stage biotechnology company utilizing best-in-class antibody...
Monday, November 11, 2024 1 min read
Key Takeaway: To access the live and archived webcast, please visit the Investor Relations page of Spyre's website at https://ir.spyre.com/events-and-presentations . The archived webcast will be available for a limited time on the Company's website.
About Spyre Therapeutics
For more informat
Full Press Release Details
To access the live and archived webcast, please visit the Investor Relations page of Spyre's website at https://ir.spyre.com/events-and-presentations . The archived webcast will be available for a limited time on the Company's website.